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Drug resistance and poor virological responses are associated with well-characterized mutations in the viral
reading frames that encode the proteins that are targeted by currently available antiretroviral drugs. An
integrated system was developed that includes target gene amplification, DNA sequencing chemistry (TRU-
GENE HIV-1 Genotyping Kit), and hardware and interpretative software (the OpenGene DNA Sequencing
System) for detection of mutations in the human immunodeficiency virus type 1 (HIV-1) protease and reverse
transcriptase sequences. The integrated system incorporates reverse transcription-PCR from extracted HIV-1
RNA, a coupled amplification and sequencing step (CLIP), polyacrylamide gel electrophoresis, semiautomated
analysis of data, and generation of an interpretative report. To assess the accuracy and robustness of the assay
system, 270 coded plasma specimens derived from nine patients were sent to six laboratories for blinded
analysis. All specimens contained HIV-1 subtype B viruses. Results of 270 independent assays were compared
to “gold standard” consensus sequences of the virus populations determined by sequence analysis of 16 to 20
clones of viral DNA amplicons derived from two independent PCRs using primers not used in the kit. The
accuracy of the integrated system for nucleotide base identification was 98.7%, and the accuracy for codon
identification at 54 sites associated with drug resistance was 97.6%. In a separate analysis of plasma spiked
with infectious molecular clones, the assay reproducibly detected all 72 different drug resistance mutations that
were evaluated. There were no significant differences in accuracy between laboratories, between technologists,
between kit lots, or between days. This integrated assay system for the detection of HIV-1 drug resistance
mutations has a high degree of accuracy and reproducibility in several laboratories.
Combination antiretroviral therapy prolongs survival in hu-
man immunodeficiency virus type 1 (HIV-1)-infected persons
(12), although virological failure occurs in 50% of persons in
the first year of treatment (7). Virological failure occurs be-
cause of viral resistance to drugs (4) or insufficient exposure to
drugs, as can occur due to poor adherence to prescribed reg-
imens or decreased absorption or increased clearance of drugs
(1). In retrospective studies, virological response to changes in
antiretroviral therapy is correlated with baseline resistance to
drugs, whether measured as viral genetic mutations (9, 20, 26)
or drug susceptibility phenotype (8, 9, 21). Randomized pro-
spective clinical trials have demonstrated that receiving results
of genotypic drug resistance assays prior to changes in therapy
improve virological responses (2, 10). Based on these studies of
HIV-1 genotyping assays, the Department of Health and Hu-
man Services, the International AIDS Society-USA, and the
European Guidelines group now recommend drug resistance
assays for selection of new combination antiretroviral regimens
after virologic drug failure while a patient is receiving drug
therapy (14, 19; http://www.hivatis.org) and in pregnant women
where optimal virological control is expected to help prevent
vertical transmission to the infant (5). Recent reports of high
prevalence of primary, or transmitted, drug resistance (3, 13,
18, 22, 23) and impaired virological responses in subjects ac-
quiring drug-resistant HIV-1 when first infected (11, 17) sug-
gest that resistance testing may also be warranted for drug-
naïve persons starting therapy, as recommended by the
European Guidelines group (19). The European guidelines
also recommend resistance testing of the sources of persons
presenting for postexposure prophylaxis and for children born
to mothers with detectable viremia while receiving treatment
(19).
The clinical trials demonstrating utility of drug resistance
genotyping for the selection of antiretroviral therapy were sup-
ported by centralized reference laboratories with extensive ex-
perience with viral genotypic testing. In clinical practice, drug
resistance genotypic testing is performed using a wide variety
of methods whose performance characteristics have not been
thoroughly established. Significant variations exist between
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laboratories in the extent of technical training, the reagents
used, the amplification and sequencing protocols, and datum
review and reporting procedures. This variation in methods
may contribute to the variable quality of resistance assay re-
sults that have been observed in international evaluations (24).
We now describe a multicenter blinded study of the accuracy
and reproducibility of results obtained with the TRUGENE
HIV-1 Genotyping Kit and OpenGene DNA Sequencing Sys-
tem (Visible Genetics, Inc.). This is an integrated system that
includes a training and certification program, positive and
negative control specimens, reverse transcription (RT)-PCR
amplification, dye primer labeled bi-directional sequencing,
polyacrylamide gel electrophoresis, and sequence analysis in-
cluding sequence contiguous element assembly, guided manual
editing, and an interpretative HIV-1 resistance report based on
algorithms developed and periodically revised by an interna-
tional committee of experts. The study aimed to evaluate the
accuracy of the assay system in the evaluation of plasma sam-
ples from HIV-1-infected persons and virus stocks derived
from infectious molecular clones and to determine the vari-
ability in accuracy by laboratory site, by technician, by day, and
by kit lot.
MATERIALS AND METHODS
Specimens. EDTA-treated anticoagulated blood plasma was obtained by plas-
mapheresis from nine HIV-1-seropositive subjects having HIV-1 RNA levels in
plasma ranging from 1,279 to 353,900 copies per ml (Roche Amplicor HIV-1
Monitor assay). Five of these specimens (VA-MH-001, -003, -004, -007, and -009)
are also described elsewhere (15). All plasma specimens were stored at 70°C
with no temperature fluctuation greater than 10% as determined by daily tem-
perature monitoring. Specimens were aliquoted and labeled using specimen
codes prior to distribution to study sites, where all investigators were blinded to
the specimen identity and the results of other testing sites. In comparisons
performed in the same laboratory, separate aliquots of specimens with distinct
specimen identification codes were issued to assure blinded comparisons. Spec-
imen collection was conducted using protocols approved by the Institutional
Review Board at Stanford University and the Research and Development Com-
mittee at the VA Palo Alto Health Care System.
“Gold standard” sequence determination of plasma from HIV-1-infected per-
sons. Two aliquots of 1 ml each of plasma from each subject were centrifuged at
45,000  g for 1 h at 4°C to concentrate viral particles, which were then resus-
pended in 150 l of plasma. Viral RNA from the entire volume was mixed in lysis
buffer then isolated using columns containing activated silica. The RNA was
eluted in 50 l according to the manufacturer’s recommendations (QIAamp viral
RNA kit; Qiagen Inc.). To allow broader sampling of the virus population, two
aliquots of the extracted RNA (17 l each) were independently amplified by
RT-PCR using two distinct and different primer sets, neither of which are used
in the TRUGENE HIV-1 Genotyping Kit. These extraction and amplification
conditions are sufficient to consistently amplify specimens with viral loads as low
as 60 copies per ml (R Lloyd, R. Schuurman, H. Stang, DeGroot, L. Hough, D.
Burns, R. Mathis, and P. Feorino, 3rd Int. Workshop HIV Drug Resist. Treat.
Strat., abstr. 52, 1999). PCR products were purified by agarose gel electrophore-
sis and extraction from the gel (QIAQUICK gel extraction kit; Qiagen Inc.) and
then ligated into pGEM-T vectors (Promega). The ligation products were intro-
duced into Escherichia coli by transformation followed by drug selection. The
presence of inserted patient-derived gene inserts was verified by restriction
digestion of color-selected colonies. Purified plasmid DNA was sequenced using
Cy5.0 and Cy5.5 labeled T7 and SP6 primers (5-GTAATACGACTCACTATA
GGG-3 and 5-ATTTAGGTGACACTATAGAATAC-3, respectively). Twenty
cloned sequences from each specimen were derived by using the first 10 se-
quences from each of two independent PCR amplification reactions. The con-
sensus sequence from aligned nucleotide sequences was used as the gold stan-
dard sequence from each specimen. In order to represent mixtures greater than
or equal to 30% of the plasma HIV-1 population, bases reported in at least 6 of
the 20 clones (30%) were included in the gold standard consensus sequence
using standard ambiguity codes. Viral sequences in one of the nine plasma
specimens (VA-MH-001) were difficult to clone using standard cloning tech-
niques; therefore, only 16 sequences were used to establish the gold standard
consensus in this instance.
Generation of virus stocks from infectious molecular clones. Mutant HIV-1
viruses containing 72 different drug resistance mutations were prepared from
infectious molecular clones of HIV-1. Mutant variants of HIV-1 were prepared
by site-directed mutagenesis of an infectious molecular clone of HIV-1LAI
(pLAI.2) (kindly provided by L. Montagnier through the NIH AIDS Research
and Reference Reagent Program). Mutations were introduced into the protease
(PR)- or RT-coding region of pol using the Altered Sites II in vitro mutagenesis
system (Promega, Madison, Wis.). The resulting plasmids were linearized by
restriction enzyme digestion and electroporated into CEM-SS cells to generate
infectious viruses, which were propagated to yield high-titer stocks. HIV-1 viral
load was assayed (Roche Amplicor HIV-1 Monitor), and the virus stocks were
diluted to the desired concentration in blood plasma from anti-HIV-1 seroneg-
ative donors and stored at 70°C with no temperature fluctuation greater than
10%.
Performance sites. The laboratory analyses of specimens were performed
using the TRUGENE HIV-1 Genotyping Kit assay in eight laboratories in the
United States; six laboratories were involved in the analysis of plasma samples
from infected persons and three laboratories were involved in the analysis of
virus samples prepared from infectious molecular clones. Samples were distrib-
uted among the sites in a balanced manner to maximize the power to detect
differences in assay performance between laboratory sites. All technologists
participating in the study were trained and certified to perform the TRUGENE
HIV-1 Genotyping Kit assay using standardized protocols. The training involved
1 week of practical and theoretical training at a reference laboratory (Visible
Genetics, Inc., Atlanta, Ga.) followed by proficiency testing of a blinded practice
panel and a blinded certification panel of four unknown specimens plus two
controls. Technologists were required to achieve greater than 95% sequencing
accuracy on the blinded panels.
TRUGENE HIV-1 Genotyping Kit performance. All assay procedures were
performed according to the manufacturer’s recommendations (Visible Genetics,
Inc.). Briefly, plasma viral RNA was extracted using activated silica in a column
format (QIAamp viral RNA kit; Qiagen Inc.). For this study, 140 l of uncon-
centrated plasma was mixed in a lysis buffer, placed over the column, washed,
and then eluted in 60 l. An aliquot of 17 l of extracted RNA eluate was mixed
with RT-PCR reagents containing RNase inhibitor, Taq polymerase, sequence
specific primers, dATP, dCTP, dGTP, dTTP, magnesium, dithiothreitol, and pH
buffers. The RT-PCR primers used in the kit amplify the entire protease and the
first 250 codons of reverse transcriptase as a single amplicon. The reverse tran-
scriptase reaction was performed at 90°C for 2 min, followed by incubation at
50°C for 5 min, at which point reverse transcriptase enzyme was added to the
reaction mixture, which was then incubated for an additional 55 min before the
reaction was terminated at 94°C for 2 min. DNA amplification was performed in
the same tube using cycling conditions of 94°C for 30 s, 57°C for 30 s, and 68°C
for 2 min for 20 cycles; this was followed by cycling conditions of 94°C for 30 s,
60°C for 30 s, and 68°C for 2.5 min for 17 cycles; and the cycling finished with one
cycle of 68°C for 7 min and then a 4°C hold. Unpurified RT-PCR product (5 l)
from each specimen was used in each of 16 sequencing reactions, based on the
CLIP principle (25), and employing four pairs of primers that sequence the
protease reading frame (two pairs) and the beginning and middle of the reverse
transcriptase reading frame (one pair each). For each segment, four sequencing
reactions were used with four dideoxy terminators (ddATP, ddCTP, ddGTP, and
ddTTP), Cy5-labeled forward primers, and Cy5.5-labeled reverse primers to
generate CLIP sequencing products over 30 reaction cycles (94°C for 20 s, 56°C
for 20 s, 70°C for 1.5 min) followed by a 5-min terminal extension at 70°C.
Unpurified CLIP sequencing products were analyzed using 6% polyacrylamide–
urea–Tris-borate-EDTA gel electrophoresis for 50 min at 2,000 V, with pre-
manufactured Microcel cassettes, which were cast using Surefill 6% sequencing
polyacrylamide gel cartridges (Visible Genetics, Inc.), containing premeasured
amounts of acrylamide, urea, and Tris-borate-EDTA, which were polymerized
using UV light.
Sequence data analysis. Sequence data acquisition and analysis were per-
formed using the Gene Objects software (Visible Genetics, Inc.). The software
allows automated and real-time acquisition of sequence data from the DNA
sequencers (Long Read Tower Sequencers). Sequence fragments are assembled
automatically and electropherogram patterns are displayed for semiautomated
review after alignment with a clade B HIV-1 reference sequence (HIV-1LAI) and
a mutated reference sequence containing codon changes typically observed in
drug-resistant HIV-1. The use of both mutant and wild-type reference sequences
serves to minimize biases toward the wild type during manual editing. The
software can be set to skip automatically to positions where there are differences
in base identification between the forward and reverse sequencing reactions or
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between the determined sequence and either of the reference strains or if results
from only one sequencing direction is available. For this study, manual editing
was limited to bases that were discordant between the two sequencing reactions.
The edited sequences were exported from the software for analysis.
Statistical analysis. All statistical analysis was performed by an independent
contractor (HHI, Hunt Valley, Md.), who had no communication with any of the
laboratory testing sites. The sequences derived from each assay were compared
to the gold standard sequence to assess the extent of agreement. Agreement was
compared for all nucleotide positions, for all codons, for codons that were
mutated in the gold standard (relative to HIV-1LAI), for codons that were wild
type in the gold standard, and for codons that have been associated with de-
creased susceptibility or poor virological response to antiretroviral therapies.
Only exact agreement was scored as an accurate result, defined as detection of all
of the bases present in the gold standard sequences and no other bases. For
example, if the gold standard sequence indicated that A was the predominant
base present at a given site and G was present in 6 of 20 clones, the result would
be scored as accurate only if A and G were detected and C and T were not
detected. Detection of C would be considered inaccurate in the a priori data
analysis plan even if C were detected in at least one of the gold standard
sequences, but at a frequency of less than 30% of the clones. The mutation
recognition rate was defined as the portion of mutated codons (relative to
HIV-1LAI) that were exactly detected by the assay. The wild-type recognition rate
was defined as the proportion of nonmutant codons that were exactly detected by
the assay. Codons associated with antiretroviral resistance were defined as
codons that have been associated with virological drug failure in vivo, decreased
drug susceptibility in vitro, or drug selection in tissue culture, as compiled in
published tables (6, 14). Differences in accuracy between laboratories, techni-
cians, kit lots, and days were evaluated for statistical significance using analysis of
variance across all groups, followed by pairwise comparisons if there was evi-
dence of differences. A secondary analysis, designed after the primary analysis,
allowed results to be considered accurate if bases or codons present in the gold
standard in fewer than 30% of clones were detected, provided that all bases
present in more than 30% of the gold standard clones were also detected. The
accuracy of replicate testing of virus stocks derived from infectious molecular
clones was calculated for each of the 72 drug resistance mutations present in the
panel.
Nucleotide sequence accession numbers. The consensus sequences from the
gold standard sequencing procedures have been submitted to GenBank with
accession numbers AF472535 to AF472552.
RESULTS
Gold standard sequences. Tables 1 and 2 list the virus prep-
arations that were evaluated in this study. Nine specimens were
blood plasma derived from HIV-1-infected persons (Table 1),
and 10 specimens were derived from stocks of infectious mo-
lecular clones spiked into blood plasma from seronegative per-
sons (Table 2). Of the HIV-1-infected persons, seven were
antiretroviral experienced and six were taking antiretroviral
therapy at the time of specimen collection. The amino acid
substitutions associated with drug resistance are listed, indicat-
ing mixtures whenever detected in more than 30% (e.g., 6 of
20) of the clones sequenced per specimen. The amino acid
changes detected in the gold standard sequences are consistent
with the prior and current antiretroviral therapy of these sub-
jects. In addition to the mutations associated with drug resis-
tance, there were silent and nonsilent mutations detected in
each specimen derived from HIV-1-infected persons.
Testing process for plasma specimens from infected per-
sons. Overall, each of the nine plasma specimens was tested at
least 18 times, sometimes 36 times, in a blinded fashion using





Antiretroviral therapy Gold standard resistance genotype
Current Other prior PR RT
VA-MH-001 353,900 None Zidovudine, didanosine,
zalcitabine, stavudine
L63P
VA-MH-002 1,722 Stavudine, didanosine,
efavirenz
Zidovudine, lamivudine L10I, L63P M41L, K101E, K103N, M184M/I/V,
T215Y/F, K219K/Q
VA-MH-003 2,618 Zidovudine, lamivudine None M184V
VA-MH-004 1,279 Stavudine, lamivudine,
nevirapine
Zidovudine, saquinavir D67N, K70R, K103N, M184V,
K219Q
VA-MH-005 1,433 Zidovudine, lamivudine None K20R, L63P, V77I M41L, M184V, T215Y
VA-MH-006 28,167 None None M36I
VA-MH-007 28,881 None None M36M/I











L10I, L63P K103N, M184V, T215F
TABLE 2. Infectious molecular clones diluted in seronegative blood plasma
Specimen
identification no.
Gold standard resistance genotype
PR RT
MIC-5 20R, 63P, 77I, 82T, 90M 62V, 74V, 75T, 77L, 115F, 116Y, 151M, 184V, 215F, 219E
MIC-9 10R, 30N, 71V, 90M 41L, 69D, 70R, 181C, 215Y
MIC-11 50V 188C, 190A, 210W, 219Q
MIC-13 None 181I, 184I
MIC-14 10V, 20M, 32I, 33F, 46L, 54L, 71T, 73A, 82F 98S, 103T
MIC-15 None 188H, 190S, 236L
MIC-16 10I, 24I, 36I, 73S, 82S, 88D 98G, 100I, 101E
MIC-17 None 179D, 188L, 190E
MIC-18 10F 50V, 69N, 70E, 75I
MIC-19 46I, 47V, 48V, 50V, 54V, 82A, 84V 65R, 67N, 103N, 106A, 108I
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the OpenGene system. All panels included at least one sample
from each of the nine specimens and duplicate samples for an
additional six specimens. The assays were performed by nine
technicians in six laboratories using three kit lots. All of the
technicians originally proposed to participate in the study
passed a proficiency panel and a certification panel: seven of
nine passed on the first attempt and two passed on the second
attempt. Taken together, 324 assays were completed, repre-
senting 270 blinded specimens and 54 negative controls. Of the
six laboratories, all had prior experience with DNA sequencing
and were based at academic centers, one was licensed for
clinical diagnostic testing, and none had any direct role in the
development of Visible Genetics technology. Data submitted
from these laboratories indicated that 194 (72%) of the test
samples provided reportable results on the first assay attempt,
while 76 (28%) of the test samples required some stage of the
assay to be repeated, including 15 (5%) test samples repeated
because of deviations from the study protocol (e.g., use of the
incorrect kit lot). Among assays repeated due to inadequate
sequence data, 38% required repeated gel electrophoresis,
24% required repeated CLIP reactions, 25% required repeat
from RT-PCR, and 13% required repetition of the entire assay
starting with RNA extraction. Two sequencing towers from
one investigational site were replaced, one due to an unex-
plained error message and the other due to a failed internal
heating plate temperature check. No other equipment replace-
ments were required. A requirement for Food and Drug Ad-
ministration submission was to report any injuries to those
operating the system; there were none reported in this study.
Overall accuracy in clinical plasma samples. The overall
accuracy of the base detection was 98.7% counting only exact
matches, defined as the detection of all of the bases present in
at least 30% of the gold standard clones and no other bases
(Table 3) (30% rule). Detection at sequence positions with
pure wild-type codons in the gold standard clones was more
accurate than detection at positions with some evidence of
mutation, which frequently represented mixtures of bases (0.99
versus 0.82 for wild-type and mutant detection, respectively). A
large portion of results deemed inaccurate using the 30% rule
were due to detection of sequence variants that were present in
less than 30% of the gold standard clones, which was the cutoff
for detection established a priori for the data analysis plan. A
secondary analysis was performed which allowed detection of
bases or codons to be considered accurate provided that the
base or codon was present in at least one of the gold standard
clones (e.g., 1 of 20 or 5%), and all of the bases or codons
present in at least 30% of the gold standard clones were de-
tected in the assay (Table 3, 5% rule). This secondary analysis
revealed substantially higher accuracy using the 5% rule to
define the gold standard. For example, accuracy of mutation
detection improved from 0.82 to 0.94 using the 5% rule. Wild-
type mutation recognition agreement remained higher than
the mutation recognition agreement rate, as expected, because
wild-type codons by definition had no variation in the se-
quences used to define the gold standard, while mutant codons
could represent any mixture of mutant and wild-type codons.
There was no difference in assay accuracy at sequence posi-
tions that are known to be important for drug resistance and all
other positions.
Accuracy in clinical plasma samples across laboratory sites,
technicians, kit lots, and days. There were no significant vari-
ations in exact base to base accuracy between the six study sites
(accuracy range, 98.43 to 98.84%; P  0.84), nor between two
different technicians at each of three sites (accuracy range,
98.13 to 98.99%; P  0.43), nor between two consecutive
testing days at each of three sites (accuracy range, 98.03 to
98.85%; P  0.52), nor between three kit lots evaluated at each
of three sites (accuracy range, 98.65 to 98.91%; P  0.94).
Similarly, there were no differences in other measures of ac-
curacy (codon to codon, mutation recognition, and wild-type
recognition for all codons and drug resistance codons).
Accuracy in virus samples prepared from infectious molec-
ular clones. An analysis was performed to assess accuracy of
detection of the entire spectrum of mutations associated with
drug resistance in virus stocks derived from infectious molec-
ular clones of HIV-1. Ten HIV-1 stocks derived from infec-
tious molecular clones were spiked into plasma from HIV-1-
seronegative donors and diluted to a concentration that just
exceeded 10,000 HIV-1 RNA copies/ml. The infectious molec-
ular clones were constructed to carry multiple antiretroviral
resistance-associated mutations (Tables 1 and 2) and were
sequenced 10 times each using the TRUGENE HIV-1 Geno-
typing Kit. Taken together, the panel contained 10 virus stocks
containing 72 different drug resistance mutations. In a blinded
fashion, the panel was tested six times in one laboratory and
two times in each of two other laboratories. Fifty-four of 72
resistance mutations were correctly identified in all 10 replicate
tests, and the remaining 18 mutated codons were correctly
identified in 90% of test results. Fingerprint analysis of nu-
cleotide sequences revealed that results from two aliquots of
two specimens from one of the laboratory sites appeared to
have been contaminated with sequences from another HIV-1
isolate, unrelated to the virus in the panel (data not shown).
When results of these two contaminated sequences were ex-
cluded from the analysis, 31 of 31 (100%) resistance mutations
in PR and 40 of 41 (97.6%) resistance mutations in RT were
correctly identified in all of the remaining assay results; one
RT mutation (K101E) was correctly identified in 9 of 10 (90%)
of the test results.
Analysis of codon misidentifications in plasma specimens
from infected persons. All assay results (n  90) that were used
to compare assay performance between six laboratory sites
were also used for a detailed analysis of the clinical implica-
tions of codon misidentifications that occurred in the course of
TABLE 3. Accuracy of the TRUGENE HIV-1 genotyping kit
Comparison
30% rule 5% rule
Agreement SD Agreement SD
Base to base 0.987 0.01 0.993 0.01
All codons
Codon to codon 0.986 0.01 0.992 0.01
Mutation recognition agreement 0.82 0.17 0.94 0.07
Wild-type recognition agreement 0.99 0.01 1.00 0.01
Resistance codons
Codon to codon 0.976 0.03 0.985 0.02
Mutation recognition agreement 0.76 0.03 0.93 0.11
Wild-type recognition agreement 0.99 0.02 1.00 0.01
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this study. In this analysis, we considered 54 codon positions
that have been associated with drug resistance, virological drug
failure, or drug selection (6). Of the 4,860 drug resistance
codon positions evaluated (i.e., 90 assays  54 codon positions
per assay), assay results did not exactly match the gold stan-
dard at 70 (1.4%) positions, using the 5% rule to define the
gold standard (Table 4). Of the 70 misidentified codon posi-
tions, 3 (4.3%) proved to be due to mislabeling of one speci-
men aliquot prior to distribution to one of the laboratories.
Among the remaining 67 misidentified codon positions, the
assay correctly identified at least one (but not all) of the codons
present in the gold standard. In 61% (41 of 67) of the codon
positions, the assay identified a codon that was not present in
the gold standard, in addition to the gold standard codon. In
the other 39% (26 of 67) of codon positions, the assay detected
only one of several codons that were present in the gold stan-
dard. The majority (n  55 of 67; 82%) of the codon misiden-
tifications occurred at five codon positions (PR 10 and 63 and
RT 184, 210, and 215) in three specimens (Table 4). Test
results for these codon positions were identical in the majority
of independent assays, indicating a high degree of concordance
between laboratories despite discordance with the gold stan-
dard. The remaining 12 codon sites that were not exactly
matched with the gold standard were distributed across eight
sites in three specimens.
The clinical relevance of the misidentified codon sites was
assessed by comparing effects on assay interpretation, taking
into account the other mutations that were detected in the
same test result. There were 11 tests of one specimen (VA-
MH-005) that indicated the presence of the RT L210W muta-
tion as a mixture with wild-type, while the RT L210W mutation
was not detected in any of the clones used to define the gold
standard. The RT L210W mutation contributes to nucleoside
analogue resistance, which was also indicated in all tests of this
specimen by the RT T215Y, M184V, and M41L mutations.
The RT L210W mutation was detected in 11 of 12 (91%)
independent assays, indicating a high degree of concordance
between laboratories. According to the interpretation algo-
rithm used during this study (GuideLines Rules version 4.0;
Visible Genetics, Inc.), the detection of RT L210W in the
presence of the other mutations would have increased the
predicted level of resistance to stavudine, didanosine, and zal-
citabine from “possible resistance” to “resistance.” No codon
misidentification was associated with a change in interpreta-
tion from “no evidence of resistance” to any of the resistance
categories, or the reverse. The remaining 56 codon misidenti-
fications in this study would not have affected the assay inter-
pretation. Thirty-four codon mismatches involved amino acids
associated with drug resistance, but these would not have af-
fected the assay interpretation, because other mutations were
consistently detected that were sufficient to predict resistance
patterns. For example, detection of only RT M184V in a spec-
imen (VA-MH-002) is sufficient to indicate resistance to lami-
vudine, even though RT M184I and wild-type sequences were
also present in the gold standard. Twelve codon mismatches
involved detection of a proline in addition to leucine at PR
codon 63 in one specimen (VA-MH-001), which has no clinical
relevance because PR codon 63 is commonly polymorphic, the
proline is insufficient to impair virological responses, and there
was no other evidence of protease inhibitor resistance. Mis-
matches at other codons (n  10) are expected to have no
clinical relevance because the additional amino acid that was
detected in the assay has not been associated with drug resis-
tance (e.g., PR V82I, RT V179I, and RT K65E). Overall,
codon misidentification at resistance sites occurred infre-
quently, and the majority of identification errors would have
been insufficient to alter interpreted resistance patterns.
DISCUSSION
The TRUGENE HIV-1 Genotyping Kit proved to have a
consistently high degree of accuracy and reproducibility during
an extensive blinded evaluation in several laboratory sites using
several technicians over several days and three kit lots. In all




Gold standard codon Codon detected No. (%) of assays withmismatch (n  12)
Clinical relevance of codon
mismatch
VA-MH-001 PR L63 PR L63L/P 12 (100) None
VA-MH-001 PR V82 PR V82V/I 8 (67) None
VA-MH-002 RT M41 M41M/L 1 (8) None
VA-MH-002 RT L100 L100L/I 1 (8) None
VA-MH-002 RT K101E RT K101K/E 3 (25) None
VA-MH-002 RT M184M/V/I RT M184V 12 (100) None
VA-MH-002 RT Y215T/Y/F RT T215Y 12 (100) None
VA-MH-002 RT K219K/Q RT K219 2 (17) None
VA-MH-004 RT K65 RT K65K/E 1 (8) None
VA-MH-004 RT K101 RT K101K/Q 1 (8) None
VA-MH-005 RT V179 RT V179V/I 1 (8) None
VA-MH-005 RT L210L RT L210L/W 11 (91.7) nRTIa resistance overestimated
VA-MH-005 RT K219 RT K219K/E 1 (8) None
VA-MH-008 PR L63P PR L63L/P 1 (8) Mislabeled specimen
VA-MH-008 PR L90M PR L90 1 (8) Mislabeled specimen
VA-MH-008 RT M184V RT M184 1 (8) Mislabeled specimen
Total 70
a nRTI, nucleoside reverse transcriptase inhibitor.
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laboratories, the base-to-base accuracy was higher than 99%
and mutation recognition rates were greater than 82%. Of the
270 assays performed in this study, 259 (96%) assays yielded
drug resistance interpretations that exactly matched interpre-
tations derived from the gold standard sequences, and the
other 11 (4%) assays provided partially matching interpreta-
tions.
Several factors are likely to have contributed to the accuracy
and reproducibility of this assay. First, the establishment of
explicit training procedures and proficiency evaluation is im-
portant, especially for clinical laboratories where medical tech-
nologists may not have training or prior experience in molec-
ular biology. Second, the detailed and explicit protocol for the
assay contributes to consistent performance, which probably
accounts for the improved performance of kit-based assays
versus home brew genotyping assays in a recent international
proficiency evaluation (W. Keulen, D. Brambilla, M. Buimer,
J. Tijnagel, J. Bremer, S. Land, L. de Graaff, H. Versteeg, C.
Boucher, and R. Schuurman, 5th Int. Workshop Drug Resist.
Treat. Strat., abstr. 166, 2001; L. Shaker-Irwin, A. Scarsella, E.
Rogolsky, J. Stryker, and S. Day, 5th Int. Workshop Drug
Resist. Treat. Strat., abstr. 160, 2001). Third, the use of dye-
labeled primers has been associated with more consistent de-
tection of mixtures of sequences compared with dye-labeled
terminators, which may have biased base incorporation rates
depending on adjacent sequences. Fourth, the automated data
acquisition, analysis, and reporting helps eliminate transcrip-
tion errors which have accounted for a large portion of se-
quencing discrepancies in other studies (M. Hoover, D. Went-
worth, J. Neaton, et al., 4th Int. Workshop HIV Drug Resist.
Treat. Strat., abstr. 78, 2000). Fifth, strict adherence to good
manufacturing practices during production of the of the kit, as
well as hardware associated with the assay, may explain the
lack of variation in accuracy from lot to lot. Finally, the TRU-
GENE HIV-1 Genotyping Kit has been simplified by elimina-
tion of DNA purification steps after the RT-PCR and the
CLIP sequencing reactions, by use of the novel CLIP reaction
and by use of preformed gel cassettes. These simplifications
serve to make the assay more robust through minimization of
assay steps.
The results of two assays of infectious molecular clones of
HIV-1 were invalidated due to presence of a contaminating
HIV-1 sequence. Following completion of data analysis, se-
quence contamination was investigated using the Genetic Fin-
gerprint function of the OpenGene software. This software
function compares the pattern of polymorphisms and muta-
tions of a sequence to all other sequences in the software
library’s database. Sequences showing identity with another
sequence in the database (other than those from the same
patient) suggest the possibility of contamination and should be
investigated prior to reporting the result. For this study of
coded specimens, participating laboratories were instructed
not to use the Fingerprint function, which could have biased
accuracy results by revealing virus identities in the panel,
thereby compromising blinding procedures. Use of the Finger-
print function is, however, recommended during routine labo-
ratory use and was found to detect the contamination events
that occurred in this study. Stringent precautions against con-
tamination when performing PCR-based tests are needed (16),
including architectural separation of laboratory areas used for
PCR setup and DNA analysis, use of negative template con-
trols, and sequence comparison with sequences determined
previously in the same laboratory, as with fingerprinting. Uracil
N-glycosylase is also used to decrease carry-over contamina-
tion in PCR-based assays, but was not included in the formu-
lation of the TRUGENE assay which minimizes and detects
contamination events by other methods. Further, uracil N-
glycosylase treatment would not eliminate the risk of carryover
contamination during the setup of CLIP reactions utilized in
the TRUGENE assay.
Our study posed several real-life challenges to a drug resis-
tance genotyping assay, including use of plasma from HIV-1-
infected humans. Virus populations in vivo are diverse, which
poses significant challenges to molecular diagnostic assays that
involve oligonucleotide primers for amplification and sequence
detection. These challenges are addressed in the TRUGENE
HIV-1 Genotyping Kit through use of degenerate primers and
ambiguity codes that allow information about sequence mix-
tures to be retained in the report. Nevertheless, all of the
codon identification errors analyzed in Table 4 (other than
those due to mislabeling of aliquots prior to distribution to
testing sites) involved incomplete, but partially correct, iden-
tification of mixtures of codons present in either the gold
standard consensus or the assay result. Even analysis of mul-
tiple viral sequence clones from two highly sensitive PCRs, as
performed here to establish the gold standard sequence con-
sensus, does not guarantee full representation of the diversity
of clinically occurring HIV-1 populations. For example, the
consistent detection of the RT L210W mutation (as a mixture
with wild type) in 11 of 12 independent assays of specimen
VA-MH-005 suggests that the mutation was present in the
virus population at low frequency, although it was not detected
in any of the 20 clones used to establish the gold standard.
Failure to identify the mutation in the clones used for the gold
standard could occur due to random sampling error of diverse
populations. Ambiguity inherent in establishing gold standard
measurements of naturally occurring virus populations is also
indicated by the improvement in assay accuracy (Table 3) ob-
served when using the 5% cutoff to define the gold standard,
which allowed detection of codons present in less than 30% of
the virus population to be considered correct. Mutation detec-
tion in homogeneous virus stocks derived from infectious mo-
lecular clones was also found to be highly accurate and repro-
ducible, representing important measures of the assay
performance that is not confounded by virus population diver-
sity.
The challenges for training and quality control were also
increased in our study because of the involvement of multiple
laboratories (both academic and clinical), multiple testing per-
sonnel, and multiple kit lots. Use of large panels of specimens,
unique labels for all aliquots, and an external data manage-
ment and analysis agency eliminated any opportunities for
partial unblinding of analysis or reporting in our study. Hence,
we believe that the assay performance described here will re-
flect assay performance in a variety of clinical and research
laboratories. Our estimates of assay performance cannot be
directly compared with estimates based on less challenging
evaluations that involve analysis of molecular clones of HIV-1,
extensive use of reference laboratories, or proficiency panels
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that involve limited numbers of specimens and labeling that
may allow laboratories to cross-validate results prior to reporting.
After the study was completed, the TRUGENE assay that is
available to clinical laboratories was modified to include a
centrifugation step to concentrate the virus from 1 ml of
plasma prior to RNA extraction and provision of alternative
PCR primers (version 1.5). The centrifugation step was found
to decrease the minimum viral load required for genotypic
evaluation to less than 100 copies/ml (R. Lloyd, R. Schuuman,
H. Stang, DeGroot, L. Hough, D. Burns, R. Mathis, and P.
Feorino, 3rd Int. Workshop HIV Drug Resist. Treat. Strat.,
abstr. 52, 1999). The alternative primers are designed to bind
to diverse HIV-1 subtypes to permit testing of non-B HIV-1
subtypes using the TRUGENE system (L. Jagodzinksi, J.
Cooley, S. Kelly, and N. Michael, 9th Conf. Retrovir. Oppor-
tun. Infect., abstr. 594-T, 2002). The version 1.5 primers are
one of the primer sets used in this study to amplify the gold
standard sequences. Both assay modifications aim to improve
the assay success rate and did not affect the accuracy of se-
quence determinations in the clinical laboratory that partici-
pated in this study (data not shown).
The clinical utility of drug resistance genotyping assays has
been consistently demonstrated in clinical trials where labora-
tory testing is performed in reference laboratories with exten-
sive experience with molecular biology assays (2, 10). Transla-
tion of this experience from clinical trials to clinical practice
will require the availability of assay technology that can be
mastered and consistently controlled in clinical diagnostic lab-
oratories. The results of this study indicate that the TRU-
GENE HIV-1 Genotyping Kit is an accurate and robust system
suitable for clinical laboratory testing.
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